6 Investor presentation First nine months of 2024 Novo Nordisk has tripled its glob increased its GLP-1 volume mark Global number of patients on GLP-1s across diabetes and Number of patients (millions) 20 10 5% 38% 57% Aug 2021 Novo Nordisk 1 Eli Lilly 2 Others 3 % Volume 1 Includes liraglutide and semaglutide 2 Includes dulaglutide and tirzepatide 3 Includes bupropion, naltrexone, lorcaserin etc. API: Active pharmaceutical ingredient; CAPEX: Capital expenditure Source: Based on information licensed from IQVIA: IQVIA MIDAS ® monthly volume sales data for the period 01.08.2021 to 01.08.20
Download PDF file